After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst
November 16, 2022 at 14:21 PM EST
Tuesday, theFDA granted accelerated approvalforImmunoGen Inc's(NASDAQ: IMGN) Elahere (mirvetuximab ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.